TABLE 4.
Variableb | Univariate |
Multivariate |
||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Age | 0.89 | 0.45–1.41 | 0.8 | |||
Male sex | 1.25 | 0.59–2.71 | 0.56 | |||
Cause of ICU admission | ||||||
Respiratory failure | 1.42 | 0.76–2.1 | 0.09 | |||
Trauma | 1.65 | 0.87–1.98 | 0.51 | |||
Septic shock not caused by KPC-Kp or MDR-AB | 1.11 | 0.65–1.99 | 0.65 | |||
Stroke | 0.87 | 0.45–1.32 | 0.9 | |||
Cardiac/hemorrhagic shock/postsurgery | 0.65 | 0.44–1.97 | 0.09 | |||
Comorbidities | ||||||
Chronic liver disease | 2.5 | 0.22–2.8 | 0.58 | |||
Neoplasm | 0.58 | 0.18–1.8 | 0.41 | |||
Diabetes | 0.76 | 0.3–1.91 | 0.64 | |||
Heart failure | 0.78 | 0.24–2.11 | 0.6 | |||
Coronary artery disease | 0.93 | 0.45–1.93 | 1.0 | |||
Chronic renal disease | 1.04 | 0.3–3.6 | 1.0 | |||
COPD | 1.04 | 0.41–2.63 | 1.0 | |||
Previous hospitalization (90 days) | 1.14 | 0.56–2.31 | 0.72 | |||
Previous ICU admission (90 days) | 1.51 | 0.48–4.79 | 0.56 | |||
Previous surgery (30 days) | 1.25 | 0.61–2.57 | 0.58 | |||
Previous antibiotic therapy (30 days) | 2.01 | 0.98–4.13 | 0.07 | |||
Colonization at time of ICU admission | 2.27 | 1.11–4.62 | 0.03 | |||
Source of infection | ||||||
Primary bacteremia | 1.45 | 0.72–2.92 | 0.37 | |||
CVC-related bacteremia | 1.45 | 0.6–3.49 | 0.5 | |||
Pneumonia | 0.93 | 0.46–1.89 | 1.0 | |||
Catheter-related urinary tract | 1.45 | 0.62–3.4 | 0.39 | |||
SSTI | 2.18 | 0.78–6.06 | 0.2 | |||
Intra-abdominal | 0.46 | 0.13–1.55 | 0.26 | |||
Isolation of a colistin-resistant strain | 6.38 | 2.94–13.82 | <0.001 | 25.1 | 4.9–127.8 | <0.001 |
Other infections during ICU stay | 1.17 | 0.58–2.36 | 0.72 | |||
Steroid therapy during ICU stay | 0.27 | 0.07–1.02 | 0.054 | |||
Length of hospitalization | 0.76 | 0.36–1.66 | 0.6 | |||
Length of ICU stay | 1.1 | 0.31–1.33 | 0.8 | |||
Length of antibiotic therapy | 1.45 | 0.64–2.2 | 0.49 | |||
SAPS II at time of infection onset | 0.87 | 0.76–1.45 | 0.4 | |||
SAPS II at time of septic shock onset | 1.11 | 0.87–2.1 | 0.5 | |||
Use of only 1 antibiotic as definitive therapy | 0.48 | 0.09–2.57 | 0.46 | |||
Use of 2 antibiotics in combination as definitive therapy | 0.83 | 0.39–1.76 | 0.7 | |||
Use of 3 antibiotics in combination as definitive therapy | 1.05 | 0.51–2.13 | 1.0 | |||
Use of 4 antibiotics in combination as definitive therapy | 1.45 | 0.62–3.4 | 0.39 | |||
Colistin-containing regimen as definitive therapy | 1.02 | 0.5–2.05 | 1.0 | |||
Tigecycline-containing regimen as definitive therapy | 0.79 | 0.36–1.7 | 0.56 | |||
Gentamicin-containing regimen as definitive therapy | 1.46 | 0.67–3.19 | 0.42 | |||
Rifampin-containing regimen as definitive therapy | 1.28 | 0.45–3.66 | 0.78 | |||
Carbapenem-containing regimen as definitive therapy | 1.66 | 0.78–3.52 | 0.19 | |||
≥2 in vitro-active antibiotics used within 24 h | 0.1 | 0.04–0.25 | <0.001 | 0.19 | 0.04–0.85 | 0.03 |
Definitive therapy with ≥2 antibiotics displaying in vitro activity | 0.02 | 0.009–0.76 | <0.001 | 0.02 | 0.004–0.14 | <0.001 |
Time to initial definitive therapy | 0.65 | 0.23–1.12 | 0.08 |
KPC-Kp, Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
MDR-AB, multidrug-resistant Acinetobacter baumannii; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CVC, central venous catheter; SSTI, skin and soft tissue infection; SAPS, simplified acute physiology score.